Anesiva (ANSV) Announces FDA Approval of sNDA to Expand Zingo(TM) Indication to Include Adults
More News related to ANSV
- Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
- Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger
- Anesiva Receives Nasdaq Listing Compliance Notice
- Needham & Co Downgrades Anesiva (ANSV) to Hold
- Anesiva (ANSV) Announces FDA Approval of sNDA to Expand Zingo(TM) Indication to Include Adults
Anesiva, Inc. (Nasdaq: ANSV) today announced that the U.S. FDA has approved Anesiva's supplemental New Drug Application to expand the indication for Zingo(TM) to treat the pain associated with blood draws to include adults. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system was previously approved to treat the pain associated with peripheral IV insertions and blood draws in children three to 18 years of age. The notification was received according to PDUFA deadlines.
Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
